Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Birth Control Methods01:22

Birth Control Methods

5.6K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
5.6K
Proliferative Phase01:20

Proliferative Phase

1.1K
The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
1.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

948
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
948
Ovarian Cycle01:27

Ovarian Cycle

3.0K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

940
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
940
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

366
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
366

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pregnancy Test Use and Timing of Pregnancy Detection in a Prospective Cohort of Pregnancy Planners.

Obstetrics and gynecology·2026
Same author

Letter to the editor: five-year implant versus other contraception missing correct data.

Journal of medical economics·2026
Same author

Venous thromboembolism with combined oral contraceptives based on estrogen and progestin content: a disproportionality analysis of the United States Food and Drug Administration Adverse Event Reporting System database.

American journal of obstetrics and gynecology·2026
Same author

Evaluating the accuracy of CPT coding for inpatient second- and third-trimester labor induction abortion at a tertiary medical center.

Contraception·2026
Same author

Understanding support needs for people carrying pregnancies with life-limiting fetal conditions: a qualitative study.

Contraception·2026
Same author

Exploring how California obstetrician-gynecologists interpret the fetal viability concept.

Contraception·2026

Related Experiment Video

Updated: Dec 18, 2025

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.1K

Progestin-only pill use over 6 months postpartum.

Suji Uhm1, Nuria Garcia-Ruiz1, Mitchell D Creinin1

  • 1Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, United States.

Contraception
|June 17, 2020
PubMed
Summary

About half of women choosing progestin-only pills (POPs) at postpartum visits discontinue use by 3 months. Continued monitoring is essential to understand postpartum contraceptive adherence and pregnancy risk.

Keywords:
BreastfeedingHormonal contraceptionPostpartum contraceptionProgestin-only pills

More Related Videos

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse
03:43

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse

Published on: September 13, 2022

6.2K
Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
03:30

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy

Published on: October 25, 2024

2.2K

Related Experiment Videos

Last Updated: Dec 18, 2025

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.1K
Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse
03:43

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse

Published on: September 13, 2022

6.2K
Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
03:30

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy

Published on: October 25, 2024

2.2K

Area of Science:

  • Reproductive Health
  • Maternal Health
  • Contraception

Background:

  • Postpartum contraception is crucial for maternal health and birth spacing.
  • Progestin-only pills (POPs) are a common choice for postpartum women, especially those breastfeeding.
  • Understanding adherence to POPs is vital for effective family planning.

Purpose of the Study:

  • To determine the rate of progestin-only pill (POP) use at 3 and 6 months postpartum.
  • To assess adherence among women who selected POPs during their postpartum visit.

Main Methods:

  • Secondary data analysis of a prospective observational study.
  • Telephone interviews were conducted at 3 and 6 months postpartum to assess contraceptive use.

Main Results:

  • Of 440 women, 92 (20.9%) chose POPs at the postpartum visit.
  • POP use was 52.4% at 3 months and 43.4% at 6 months.
  • Consistent use at both 3 and 6 months was observed in 42.1% of women.

Conclusions:

  • Approximately half of women who intend to use POPs postpartum discontinue use by 3 months.
  • Further research into sexual activity and breastfeeding patterns is needed to clarify pregnancy risks for non-users.